Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash from Investing Activities: 2021-2025

Historic Cash from Investing Activities for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Sep 2025 value amounting to $5.2 million.

  • Amylyx Pharmaceuticals' Cash from Investing Activities fell 86.51% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.6 million, marking a year-over-year increase of 56.81%. This contributed to the annual value of $75.7 million for FY2024, which is 17.81% down from last year.
  • Amylyx Pharmaceuticals' Cash from Investing Activities amounted to $5.2 million in Q3 2025, which was down 77.23% from $23.0 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Cash from Investing Activities registered a high of $123.2 million during Q2 2023, and its lowest value of -$228.2 million during Q4 2022.
  • In the last 3 years, Amylyx Pharmaceuticals' Cash from Investing Activities had a median value of $20.9 million in 2023 and averaged $13.8 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first tumbled by 709,264.29% in 2022, then surged by 2,661.59% in 2023.
  • Amylyx Pharmaceuticals' Cash from Investing Activities (Quarterly) stood at $2.8 million in 2021, then plummeted by 8,208.74% to -$228.2 million in 2022, then soared by 109.17% to $20.9 million in 2023, then spiked by 210.54% to $65.0 million in 2024, then tumbled by 86.51% to $5.2 million in 2025.
  • Its Cash from Investing Activities was $5.2 million in Q3 2025, compared to $23.0 million in Q2 2025 and -$43.7 million in Q1 2025.